AMRX's Quality Score rose 1 point on Tue, Nov 10, to 19. Its price closed above its average of the last 21 days, which is rising (2 chart checks started).
Follow AMRX's trial news. Pro members can get an alert when Amneal Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 10% from Nov 5 to Nov 10.
| The company | Free cash flow up 14x |
| Latest filing | 10-Q, Nov 9 |
After its last 4 reports it closed -3.2% on average, higher 0 of 4 times.
No shelf registration or at-the-market program on file in the last three years.
Director John Kiely sold 50,000 shares on Aug 13. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. AMRX scores 19 today, against a median of 14 over its last 20 recorded sessions.
AMRX is #9 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 9 |
Net income over four quarters: AMRX $133M, BHC -$841M, ALKS -$351K.
Expected to report Fri Feb 26, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $862.7M, 10% more than a year ago; a loss of $0.06 a share, from a profit of $0.01.
“Affordable Medicines net revenue increased 19%, driven by biosimilars, women’s health patches, and new launches.”
AMRX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Adjusted EBITDA in the third quarter of 2026 was $207 million, an increase of 30% compared to the third quarter of 2025, reflecting higher revenue, higher gross profit, and lower operating expenses.”
From its results filing (SEC filing · Nov 3)
Sales grew 8.7% a year over 5 years, fiscal 2020 to 2025.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | -2.5% | -1.1% | +4.1% |
| Jul 30, 2026 | -3.0% | -3.1% | -3.4% |
| May 7, 2026 | -0.7% | -3.8% | -10.9% |
Sales grew in six of the last seven years, to $3B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 60.7, MACD below signal, above both averages. Not scored.
3 insiders sold $7.2M across 4 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AMRX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
“The pharmaceutical industry is highly competitive and influenced by technological innovation, new developments, government regulations, health care legislation, access to capital, and other factors.”
AMRX scores 19 today, which Breakaway calls Excellent. It is #9 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 10% from Nov 5 to Nov 10. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AMRX scores 19 today, which Breakaway calls Excellent (15 to 19). That is #9 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AMRX's 19.
3 insiders sold $7.2M across 4 filings in the last 6 months. No open-market buys on record. The newest is John Kiely, Director, who sold $882K on Aug 13. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.